Articles related to HEALTHCARE ACCESS

The event will be held on Tuesday, April 11th, 2023 from 5:00pm – 9:00pm at The Hermitage Hotel in Nashville, TN, in the Grand Ballroom. Tennessee Oncology’s Stephen Schleicher, MD, and Larry Bilbrey will be your hosts for this one-night event, which will provide commentary on how cancer care has become more complicated over the last 15 years and how data is disrupting delivery today and in the future, from the private sector to tech companies.

To assist retail pharmacies in filling the care gap left by physician shortages and transitioning to an effective, patient-centric clinical services business model, real-time communication and seamless data sharing among pharmacists, diagnostic providers, physicians, and patients are required. Linking the care team in a way that allows for not only efficient care delivery but also efficient provider billing with full interoperability will be critical to pharmacies’ long-term success as clinical service providers.

Mike Serbinis, CEO of League; Pete Anevski, CEO of Progyny; John Erwin, CEO of Carenet Health; Mick Mazour, president of Carenet Health; BJ Schaknowski, CEO of symplr; Tanja Dowe, CEO of the Debiopharm Innovation Fund; Derek Streat, Co-founder and CEO of DexCare; and Kimberly O’Loughlin, CEO of Health Recovery Solutions, provide their thoughts on this year’s meeting, with value-based care, healthcare technology, hospital medicine, and the overall economy being the familiar strings.

According to a University of Washington research, only 40% of rural counties nationally had at least one licensed physician who could prescribe buprenorphine in 2016. The analysis discovered that by 2020, that number had increased to 63%. The increase was attributed by the study to modifications in federal regulations that permit NPs, PAs, and other healthcare professionals to prescribe buprenorphine. Only doctors could perform this in the past, and many remote counties lacked any. In 2002, Suboxone received approval from federal regulators, providing a new option for addiction treatment in communities without methadone facilities. Marshalltown, a town of 27,000 people encircled by rural areas, offers a feasible alternative, according to Andrea Storjohann, NP.

Teva Pharmaceuticals is the primary supplier of both branded and generic versions of the stimulant, which is approved to treat ADHD and narcolepsy. Teva has cited increased demand, workforce shortages, and manufacturing disruptions due to packaging constraints as reasons for the supply problems.

A cohort study of 1,024 patients at an urban academic medical center discovered that 13% of oral anticancer drug prescriptions were never filled. The most common reason for failure to receive an oral anticancer drug prescription was due to patient and clinician decision-making; 13% of cases of failure to receive an oral anticancer drug prescription were directly associated with financial access issues.